NEW YORK, Sept. 13, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Forterra, Inc. securities (NASDAQ:FRTA) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with Forterra’s October 21, 2016 initial public offering (the “Offering”) of the important October 13, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Forterra investors under the federal securities laws.
To join the Forterra class action, go to the firm’s website at http://rosenlegal.com/cases-1195.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The complaint alleges that the Registration Statement used to conduct the IPO contained inaccurate statements and omitted facts necessary to make other statements made therein not misleading. Among other things, the Registration Statement failed to disclose, at the time of the IPO, that organic sales in Forterra’s Drainage and Water segments had significantly declined, that Forterra was experiencing increased pricing pressure due to competition and continued softness in its concrete and steel pipe business, that Forterra had been losing business in its important pipe and precast business due to in large part to operational problems at its production plants, and that Forterra had undisclosed material weaknesses in its internal controls that prevented it from accurately reporting and forecasting its financial results. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1195.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Italy Fines Apple €98.6 Million Over App Store Dominance
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



